Compare · DVA vs LSTA
DVA vs LSTA
Side-by-side comparison of DaVita Inc. (DVA) and Lisata Therapeutics Inc. (LSTA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DVA and LSTA operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- DVA is the larger of the two at $15.12B, about 993.9x LSTA ($15.2M).
- LSTA has been more active in the news (5 items in the past 4 weeks vs 1 for DVA).
- DVA has more recent analyst coverage (13 ratings vs 0 for LSTA).
- Company
- DaVita Inc.
- Lisata Therapeutics Inc.
- Price
- $235.33+0.47%
- $1.67-19.90%
- Market cap
- $15.12B
- $15.2M
- 1M return
- +10.44%
- -
- 1Y return
- +61.91%
- -
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 1
- 5
- Recent ratings
- 13
- 0
DaVita Inc.
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services; vascular access services; clinical research programs; physician services; and comprehensive care services. As of December 31, 2020, it provided dialysis and administrative services in the United States through a network of 2,816 outpatient dialysis centers serving approximately 204,200 patients; and operated 321 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 36,700 patients. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
Latest DVA
- DaVita Inc. Schedules 2nd Quarter 2026 Investor Conference Call
- Chief Legal & Pub. Affairs Off Waters Kathleen Alyce sold $3,210,377 worth of shares (15,405 units at $208.40) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 109,194 units (SEC Form 4)
- Chief Executive Officer Rodriguez Javier sold $14,532,108 worth of shares (69,407 units at $209.38), decreasing direct ownership by 8% to 840,408 units (SEC Form 4)
- SEC Form 11-K filed by DaVita Inc.
- DaVita Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Yale Phyllis R gifted 5,038 shares, decreasing direct ownership by 35% to 9,525 units (SEC Form 4)
- Director Pullin Dennis W was granted 250 shares, increasing direct ownership by 10% to 2,671 units (SEC Form 4)
- Director Schoppert Wendy Lee was granted 250 shares (SEC Form 4)
- Director Moore Gregory J. was granted 250 shares, increasing direct ownership by 3% to 7,813 units (SEC Form 4)
- Director Arway Pamela M was granted 250 shares, increasing direct ownership by 0.94% to 26,945 units (SEC Form 4)
Latest LSTA
- Lisata Therapeutics Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Other Events
- Amendment: SEC Form SC 14D9/A filed by Lisata Therapeutics Inc.
- Lisata Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement
- Amendment: SEC Form SC 14D9/A filed by Lisata Therapeutics Inc.
- Amendment: SEC Form SC 14D9/A filed by Lisata Therapeutics Inc.
- Amendment: SEC Form SC 14D9/A filed by Lisata Therapeutics Inc.
- SEC Form SC 14D9 filed by Lisata Therapeutics Inc.
- Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.
- SEC Form SC14D9C filed by Lisata Therapeutics Inc.
- Lisata Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement